Turka Laurence A.

Chief Scientific OfficerRubius Therapeutics, Inc. (RUBY) · full profile →Form 4 · filed Feb 1, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$17K
Net Open-Market Flow
-$17K
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2022Sell(S)3K$6.57$17K5K
Jan 29, 2022Option exercise(M)7K7K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2022Grant(A)35K$035K
Jan 31, 2022Grant(A)144K$0144K
Jan 29, 2022Option exercise(M)7K$022K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001179110-22-000693) within minutes of acceptance. Every field above traces to the original document. Verify it directly: